PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 259 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... February 10, 2025 European Lung Cancer Virtual Congress 2021, 25-27 March [Event Announcement] March 12, 2021 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... May 9, 2025 Load more HOT NEWS Talking About Your Sexual Orientation and Gender Identity With Your Cancer... This Program Provides Free Mammograms And Breast Cancer Treatment Services To... Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer
